Central Infusion of Angiotensin II Type 2 Receptor Agonist Compound 21 Attenuates DOCA/NaCl-Induced Hypertension in Female Rats
Overview
Endocrinology
Affiliations
The present study investigated whether central activation of angiotensin II type 2 receptor (AT2-R) attenuates deoxycorticosterone acetate (DOCA)/NaCl-induced hypertension in intact and ovariectomized (OVX) female rats and whether female sex hormone status has influence on the effects of AT2-R activation. DOCA/NaCl elicited a greater increase in blood pressure in OVX females than that in intact females. Central infusion of compound 21, a specific AT2-R agonist, abolished DOCA/NaCl pressor effect in intact females, whereas same treatment in OVX females produced an inhibitory effect. Real-time RT-PCR analysis revealed that DOCA/NaCl enhanced the mRNA expression of hypertensive components including AT1-R, ACE-1, and TNF-α in the paraventricular nucleus of hypothalamus in both intact and OVX females. However, the mRNA expressions of antihypertensive components such as AT2-R, ACE-2, and IL-10 were increased only in intact females. Central AT2-R agonist reversed the changes in the hypertensive components in all females, while this agonist further upregulated the expression of ACE2 and IL-10 in intact females, but only IL-10 in OVX females. These results indicate that brain AT2-R activation plays an inhibitory role in the development of DOCA/NaCl-induced hypertension in females. This beneficial effect of AT2-R activation involves regulation of renin-angiotensin system and proinflammatory cytokines.
COVID-19 and thyroid function: What do we know so far?.
Rossetti C, Cazarin J, Hecht F, de Lima Beltrao F, Freitas Ferreira A, Fortunato R Front Endocrinol (Lausanne). 2023; 13:1041676.
PMID: 36601011 PMC: 9806267. DOI: 10.3389/fendo.2022.1041676.
Chen H, Peng J, Wang T, Wen J, Chen S, Huang Y Biochem Pharmacol. 2022; 208:115370.
PMID: 36481346 PMC: 9721294. DOI: 10.1016/j.bcp.2022.115370.
Chaves A, Magalhaes N, Insuela D, Rodrigues e Silva P, Martins M, Carvalho V Front Endocrinol (Lausanne). 2022; 13:1040040.
PMID: 36465619 PMC: 9712183. DOI: 10.3389/fendo.2022.1040040.
Parn K, Ling W, Chin J, Lee S Nutrients. 2022; 14(21).
PMID: 36364864 PMC: 9654342. DOI: 10.3390/nu14214605.
The Angiotensin AT Receptor: From a Binding Site to a Novel Therapeutic Target.
Steckelings U, Widdop R, Sturrock E, Lubbe L, Hussain T, Kaschina E Pharmacol Rev. 2022; 74(4):1051-1135.
PMID: 36180112 PMC: 9553111. DOI: 10.1124/pharmrev.120.000281.